PPIB and hepatitis A virus infection: For the big pharmaceutical companies, meanwhile, the success of the recombinant hepatitis B vaccines helped to rehabilitate the idea that vaccines could be worth investing in, paving the way for the development of other highly profitable vaccines, including the first “blockbuster” vaccines against human papilloma virus (Wailoo, Livingston, Epstein, & Aronowitz, 2010).